Adult: Aorta
Effect of ascending aorta replacement on the long-term outcomes of bicuspid aortic valve repair

Read at the 48th Annual Meeting of the Western Thoracic Surgical Association, Koloa, Hawaii, June 22-25, 2022.
https://doi.org/10.1016/j.jtcvs.2023.02.024Get rights and content
Under a Creative Commons license
open access

Abstract

Objective

The study objective was to determine the effect of sinutubular junction stabilization on long-term outcomes of bicuspid aortic valve repair.

Methods

From January 1998 to January 2020, 419 patients underwent bicuspid aortic valve repair with ascending aorta replacement and 421 without (bicuspid aortic valve repair alone). Propensity score matching (97 pairs) was used to compare outcomes.

Results

Before matching, prevalence of severe aortic regurgitation at 10 years was 5.4% after bicuspid aortic valve repair + ascending aorta replacement and 10% after bicuspid aortic valve repair alone; aortic valve gradient was 20 mm Hg after bicuspid aortic valve repair + ascending aorta replacement and 19 mm Hg after bicuspid aortic valve repair alone. Ten-year freedom from reoperation overall was 79% after bicuspid aortic valve repair + ascending aorta replacement and 75% after bicuspid aortic valve repair alone; freedom from late aortic regurgitation was 93% after bicuspid aortic valve repair + ascending aorta replacement and 92% after bicuspid aortic valve repair alone; and freedom from aortic stenosis was 87% after bicuspid aortic valve repair + ascending aorta replacement and 93% after bicuspid aortic valve repair alone. Ten-year survival was 95% after bicuspid aortic valve repair + ascending aorta replacement and 96% after bicuspid aortic valve repair alone. After matching, prevalence of severe aortic regurgitation at 10 years was 11% after bicuspid aortic valve repair + ascending aorta replacement and 9.1% after bicuspid aortic valve repair alone (P = .33); aortic valve gradient was 16 mm Hg after bicuspid aortic valve repair + ascending aorta replacement and 25 mm Hg after bicuspid aortic valve repair alone (P < .0001). Ten-year freedom from reoperation was 85% after bicuspid aortic valve repair + ascending aorta replacement and 72% after bicuspid aortic valve repair alone (P = .08) overall. Ten-year freedom from reoperation for late aortic regurgitation was 88% after bicuspid aortic valve repair + ascending aorta replacement and 86% after bicuspid aortic valve repair alone (P = .65). Freedom from aortic stenosis was 97% after bicuspid aortic valve repair + ascending aorta replacement and 91% after bicuspid aortic valve repair alone (P = .03). Ten-year survival was 96% after bicuspid aortic valve repair + ascending aorta replacement and 96% after bicuspid aortic valve repair alone (P = .16).

Conclusions

Bicuspid aortic valve repair with or without ascending aorta replacement is associated with good short- and long-term outcomes. Bicuspid aortic valve repair + ascending aorta replacement has a minimal effect on long-term repair durability. Sinutubular junction stabilization should not be performed for the sole purpose of long-term repair durability.

Key Words

aneurysm
aortic valve regurgitation
connective tissue disorder
reoperation
survival

Abbreviations and Acronyms

AR
aortic regurgitation
AS
aortic stenosis
BAV
bicuspid aortic valve
BAVr
bicuspid aortic valve repair
BAVr alone
bicuspid aortic valve repair without ascending aorta replacement
BAVr + asc
bicuspid aortic valve repair with ascending aorta replacement
CLASS
commissure, leaflet, anulus, sinus, sinutubular junction
SMD
standardized mean difference
STJ
sinutubular junction

Cited by (0)

L.G.S. is supported by the Marty and Michelle Weinberg and Family Fund; the Delos M. Cosgrove, M.D., Chair for Heart Disease Research Fund; and the HVTI Chairman's Research Fund. M.Y.D. is supported by the Haslam Family Endowed Chair in Cardiovascular Medicine. E.E.R. is supported by the Stephens Family Endowed Chair in Cardiothoracic Surgery.

All data used in this study were approved for use in research by the Cleveland Clinic Institutional Review Board, with patient consent waived (IRB #20-320, approved on 3/31/2020).